Zhejiang Tianyu Pharmaceutical Co Ltd (300702) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.063x

Based on the latest financial reports, Zhejiang Tianyu Pharmaceutical Co Ltd (300702) has a cash flow conversion efficiency ratio of 0.063x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥233.18 Million ≈ $34.12 Million USD) by net assets (CN¥3.72 Billion ≈ $544.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Zhejiang Tianyu Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Zhejiang Tianyu Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Zhejiang Tianyu Pharmaceutical Co Ltd total liabilities for a breakdown of total debt and financial obligations.

Zhejiang Tianyu Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zhejiang Tianyu Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Norion Bank
ST:NORION
0.076x
Guangzhou Hengyun Enterprises Holding Ltd
SHE:000531
0.057x
Donnelley Financial Solutions Inc
NYSE:DFIN
0.176x
ZINKA LOGISTICS SOL LTD
NSE:BLACKBUCK
-0.004x
Guardian Capital Group Ltd. Cl.A Nv (GCG-A.TO
TO:GCG-A
0.049x
Goosehead Insurance Inc
NASDAQ:GSHD
-0.142x
PennyMac Mortgage Investment Trust
NYSE:PMT
-0.688x
Prosiebensat 1 Media AG
XETRA:PSM
0.137x

Annual Cash Flow Conversion Efficiency for Zhejiang Tianyu Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Zhejiang Tianyu Pharmaceutical Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Zhejiang Tianyu Pharmaceutical Co Ltd stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥3.50 Billion
≈ $511.83 Million
CN¥344.64 Million
≈ $50.43 Million
0.099x +882.72%
2023-12-31 CN¥3.49 Billion
≈ $510.37 Million
CN¥-43.90 Million
≈ $-6.42 Million
-0.013x +9.66%
2022-12-31 CN¥3.50 Billion
≈ $511.43 Million
CN¥-48.70 Million
≈ $-7.13 Million
-0.014x +80.29%
2021-12-31 CN¥3.71 Billion
≈ $542.77 Million
CN¥-262.23 Million
≈ $-38.37 Million
-0.071x -140.30%
2020-12-31 CN¥3.55 Billion
≈ $519.00 Million
CN¥622.18 Million
≈ $91.04 Million
0.175x -16.47%
2019-12-31 CN¥2.04 Billion
≈ $298.10 Million
CN¥427.84 Million
≈ $62.61 Million
0.210x +286.63%
2018-12-31 CN¥1.45 Billion
≈ $211.66 Million
CN¥78.57 Million
≈ $11.50 Million
0.054x -20.98%
2017-12-31 CN¥1.29 Billion
≈ $188.43 Million
CN¥88.52 Million
≈ $12.95 Million
0.069x -74.66%
2016-12-31 CN¥607.31 Million
≈ $88.87 Million
CN¥164.74 Million
≈ $24.11 Million
0.271x +811.67%
2015-12-31 CN¥495.77 Million
≈ $72.55 Million
CN¥14.75 Million
≈ $2.16 Million
0.030x -83.12%
2014-12-31 CN¥456.22 Million
≈ $66.76 Million
CN¥80.44 Million
≈ $11.77 Million
0.176x +101.33%
2013-12-31 CN¥453.68 Million
≈ $66.39 Million
CN¥39.73 Million
≈ $5.81 Million
0.088x --

About Zhejiang Tianyu Pharmaceutical Co Ltd

SHE:300702 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.07 Billion
CN¥7.34 Billion CNY
Market Cap Rank
#8796 Global
#2320 in China
Share Price
CN¥21.09
Change (1 day)
-1.03%
52-Week Range
CN¥20.38 - CN¥29.77
All Time High
CN¥69.67
About

Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It provides fine chemicals and CDMO services. Zhejiang Tianyu Pharmaceutical … Read more